Making US poison centers a part of the solution to the COVID-19 pandemic

References

• FDA. Emergency Use Authorization for Vaccines Explained; 2020 Nov [cited 2021 Jan 4]; Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained
   Google Scholar
• HRSA. Countermeasures Injury Compensation Program (CICP); 2020 Nov [cited 2021 Jan 4]; Available from: https://www.hrsa.gov/cicp.
   Google Scholar
• Sharfstein JM, Goodman JL, Borio L. The US Regulatory System and COVID-19 Vaccines – The Importance of a Strong and Capable FDA. JAMA. 2021;325(12):1153.
   PubMed Web of Science ®Google Scholar
• Coalition for Epidemic Preparedness Innovations (CEPI). The Coalition for Epidemic Preparedness Innovations (CEPI) foundation takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases; 2021 [cited 2021 Jan 4]; Available from: https://cepi.net/about/whoweare/
   Google Scholar
• Law B, Sturkenboo M. Priority List of Adverse Events of Special Interest: COVID-19 (D2.3). Safety Platform for Emergency vACcines (SPEAC), Work Package: WP2 Standards and tools V2.0. 2020. May [cited 2021 Jan 4]; Available from: https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf and quarterly updates https://brightoncollaboration.us/priority-list-aesi-covid/
   Google Scholar
• The Whitehouse. National Strategy for the COVID-19 Response and Pandemic Preparedness; 2021 [cited 2021 Jan 4]; Available from: https://www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf
   Google Scholar
• Koonin LM, Sliger K, Kerr J, et al. CDC’s flu on call simulation: testing a national helpline for use during an influenza pandemic. Health Secur. 2020;18(5):392–402.
   PubMed Web of Science ®Google Scholar
• Vaccine Adverse Event Reporting System (VAERS) form with instructions; [cited 2021 Jan 4]; Available from: https://vaers.hhs.gov/pdf/VAERSForm_Dec2020.pdf
   Google Scholar
• T Shimabukuro. Covid-19, vaccine safety monitoring, CDC COVID-19 Vaccine Planning Unit (VPU), Vaccine Safety Team; 2020 Aug [cited 2020 Aug 26]; Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-08/COVID-04-Shimabukuro.pdf
   Google Scholar
• CDC. Vaccine Safety Datalink (VSD), Vaccine Safety Monitoring; 2020 [cited 2021 Feb 01]; Available from: https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html
   Google Scholar
• Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021; 384(7):643–649.
   PubMed Web of Science ®Google Scholar
• Pfizer-Biontech. COVID-19 vaccine fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19); 2021 [cited 2021 May 12]; Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=14471
   Google Scholar
• Moderna. fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease. 2019. (COVID-19) in individuals 18 years of age and older; 2021 [cited 2021 Mar 15]; Available from: https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf
   Google Scholar
• FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19); 2021 [cited 2021 Apr 19]; Available from: https://www.fda.gov/media/146304/download
   Google Scholar
• FDA. Vaccines and Related Biological Products Advisory Committee Meeting Dec 10, 2020 FDA Briefing Document Pfizer-BioNTech COVID-19; 2020 [cited 2020 Dec 11]; Available from: https://www.fda.gov/media/144245/download
   Google Scholar
• FDA. Pfizer-Biontech COVID-19 vaccine (bnt162, pf-07302048) vaccines and related biological products advisory committee briefing document meeting date; 2020 [cited 2020 Dec 11]; Available from: https://www.fda.gov/media/144246/download
   Google Scholar
• FDA. Vaccines and Related Biological Products Advisory Committee Meeting Dec 17, 2020 FDA. Briefing Document Moderna COVID-19 Vaccine; 2020 [cited 2020 Dec 19]; Available from: https://www.fda.gov/media/144434/download
   Google Scholar
• FDA. Vaccines and Related Biological Products Advisory Committee Moderna mRNA-1273 sponsor briefing document; 2020 [cited 2020 Dec 19]; Available from: https://www.fda.gov/media/144452/download
   Google Scholar
• FDA. Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021 FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19; 2021 [cited 2021 Feb 3]; Available from: https://www.fda.gov/media/146217/download
   Google Scholar
• FDA. Janssen Biotech, Inc. (a pharmaceutical company of Johnson & Johnson) COVID-19 vaccine ad26.cov2.s vac31518 (jnj-78436735) sponsor briefing document vaccines and related biological products advisory committee meeting; 2021 [cited 2021 Feb 27]; Available from: https://www.fda.gov/media/146219/download
   Google Scholar
• Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
   PubMed Web of Science ®Google Scholar
• Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125–129.
   Google Scholar
• Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, Wickner P. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA. 2021;325(15):1265–1565.
   Google Scholar
• Stolberg SG. Immunization Expert Accuses CDC and Deloitte of Stealing Her Idea. The New York Times; 2021 [cited 2021 Mar 3]; Available from: https://www.nytimes.com/2021/02/06/us/politics/coronavirus-vaccines.html?referringSource=articleShare
   Google Scholar
• CDC Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments; 2021 [cited Apr 28]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-transmission.html
   Google Scholar
• Rader B, White LF, Burns MR, et al. Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study. Lancet Digit Health. 2021;3(3):e148–e157
   Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trails. Lancet. 2021;397(10277):880.
   Google Scholar